Fosaprepitant
| Klinički podaci | |
|---|---|
| Podaci o licenci |
|
| Kategorija trudnoće |
|
| Način primene | Intravenozno |
| Pravni status | |
| Pravni status |
|
| Identifikatori | |
| CAS broj | 172673-20-0 265121-04-8 (dimeglumin) |
| ATC kod | A04AD12 (WHO) |
| PubChem | CID 219090 |
Fosaprepitant (Emend injekcije (SAD), Ivemend (EU)) je antiemetički lek, koji se upotrebljava intravenozno. On je prolek aprepitanta.
Fosaprepitant je razvio Merk. On je odobren u SAD FDA 25. januara, 2008.[1] i EMA 11. januara iste godine.[2]
Vidi još
Reference
- ^ „Drugs.com, FDA Approves Emend (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy”. Приступљено 15. 3. 2008.
- ^ „European Public Assessment Report for Ivemend (from the EMEA website)”. Архивирано из оригинала 28. 02. 2008. г. Приступљено 15. 3. 2008.
Spoljašnje veze
| Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
Content Disclaimer
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
- The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
- There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
- It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
- Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
- Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.